Barcelona Alzheimer Treatment & Research Center

Posts Tagged 2008

2008 3133K1-3001-WW

Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para valorar la eficacia y la seguridad de Bapineuzumab (AAB-001-ELN115727) en enfermedad de Alzheimer de leve a moderada y portadores de la apoliproteína Ee4. 3133K1-3001-WW Wyeth, Elan Pharmaceuticals, Inc.






Safety and efficacy of galantamine in subjects with mild cognitive impairment.

Safety and efficacy of galantamine in subjects with mild cognitive impairment. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS, GAL-INT-11/18 Study Group. Neurology 2008 May 27;70(22):2024-35.






Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer’s Disease – Data from the ICTUS Study

Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer’s Disease – Data from the ICTUS Study. Galluzzi S, Talassi E, Belussi M, Scheltens P, van de Pol L, Nobili F, Rodriguez G, Froelich L, Damian M, Martinez-Lage P, Gomez-Isla T, Reynish E, Ousset PJ, Vellas B,






Development of screening guidelines and clinical criteria for predementia Alzheimer’s disease

Development of screening guidelines and clinical criteria for predementia Alzheimer’s disease. Visser PJ, Verhey FRJ, Boada M, Bullock R, Frisoni G.B., Frölich, L, Hampel H, Jolles J, Minthon L, Nobili F,  Olde Rikkert M, Ousset P.J., Riguad A.S., Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki, M,






The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics

The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics. Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H; LEADe investigators. Alzheimer’s & Dementia 4 (2008) 145-153.






P53 phosphorylation is involved in vascular cell death induced by de catalytic activity of membrane-bound SSAO/VAP-1

P53 phosphorylation is involved in vascular cell death induced by de catalytic activity of membrane-bound SSAO/VAP-1. Solé M, Hernández-Guillamon Mar, Boada Mercè, Unzeta Mercedes.  Biochim Biophys Acta. 2008 Jun;1783(6):1085-94. PDF






A Randomized, Double-Blind, Placebo Controlled-Trial of Triflusal in Mild Cognitive Impairment: the TRIMCI study

A Randomized, Double-Blind, Placebo Controlled-Trial of Triflusal in Mild Cognitive Impairment: the TRIMCI study. Gómez-Isla T, Blesa R1, Boada M, Clarimón J, Domenech G, Ferro JM, Gómez-Ansón B, Manubens JM, Martínez-Lage JM, Muñoz D, Peña J, Torres F, on behalf of the TRIMCI study group.  Alzheimer Disease






The usefulness of standard neuropsychological testing for adults with Down syndrome and dementia

The usefulness of standard neuropsychological testing for adults with Down syndrome and dementia. Boada M, Alegret M, Buendia M, Hernández I, Viñas G, Espinosa A, Lara S, Guitart M, Tárraga L. SD International Medical Review on Down Syndrome. 2008;12(1) 2-7 PDF






Evidence of depressive symptoms in fragile-X premutated females

Evidence of depressive symptoms in fragile-X premutated females. Rodríguez-Revenga L, Madrigal I, Alegret M, Santos M, Milá M. Psychiatr Genet 2008;18(4):153-5.






2008 H6L-MC-LFAN

Efecto de la inhibición de γ-secretasa en la progresión de la enfermedad de Alzheimer (esipad): LY450139 H6L-MC-LFAN Lilly






Página 1 de 212